Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 08:06:01·⟳ 抓取 08:07:16 +1m15s·⚡ 决策 10-13 08:08:26 +1m10s·14.5 天前
ARK 公布10月12日日常调仓：减持 Personalised、DraftKings、Meta，增持 Compass Pathways 等生物科技股
这是ARK每日强制披露的ETF例行调仓汇总（AI生成稿），所有交易均为数百万美元级的小额、延续性加减仓，相对相关公司市值和基金规模可忽略，不含订单、业绩、指引、监管等任何基本面增量；历史上跟买/跟卖ARK日内调仓无统计edge，美股已收盘亦无执行窗口。
📄 原文Investing.com↗ 原文
Cathie Wood’s ARK sells stock in Personalised Inc, buys Compass Pathways
Wall Street kicks off key week of bank earnings and CPI data with a mixed session Cathie Wood’s ARK ETF published their…
不做 Personalised Inc.（PSNL.US）
ARK延续性小额减持（约1168万美元）为例行调仓、无基本面信息且已在12日成交反映，既无做多催化也不满足做空红线。
不做 Compass Pathways PLC（CMPS.US）
341万美元日常主题增持，金额小、无新增基本面，跟买无edge。
不做 DraftKings Inc.（DKNG.US）
449万美元延续性减持相对市值可忽略，不构成强空催化。
不做 Meta Platforms Inc.（META.US）
4,520股/约325万美元对META为噪音级流动，无信号意义。
不做 Alamar Biosciences Inc.（ALMR.US）
256万美元连续小额建仓属常规配置，非可交易事件。
不做 CRISPR Therapeutics AG（CRSP.US）
234万美元主题性小额买入，无基本面增量。
另有 2 腿,见展开详情。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
其余 2 腿
不做 Freenome Holdings Inc.（FRNM.US）
216万美元日常增持，信息含量不足。
不做 Guardant Health Inc.（GH.US）
213万美元/12,720股小额增持，属噪音。
研究档案
结论摘要
ARK每日交易明细属于例行、延续性的小额机械再平衡，无新增基本面信息，对任何点名标的均不构成可交易催化，故全部回避。
🔎 新鲜度:最早出现 2026-10-13 · 扩散 medium · price-in 风险 high ↗
主要风险
- 若ARK后续披露大额、非延续性的集中调仓或伴随基本面评论，需重新评估；本条不满足。
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
ARK每日强制披露的小额调仓属公开滞后信息，多为延续性加减仓，跟买跟卖缺乏正向超额收益基础；本文亦明确多笔为recent trend延续。
检索:ARK daily trade flows follow-on return edge Personalised Compass Pathways DraftKings 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认以NO_INCREMENTAL_FACT回避，不产生任何ENTER腿。
方向:未做先例统计：ARK例行每日调仓跟单是已知低/无edge类别，机制上不具备事件驱动的预期差，无需用涨幅先例校准。
涨幅量级:无可定位的正向催化，不定tp/sl。
形态:此类每日持仓披露普遍在次日无系统性同向延续，且多为延续性操作。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 19 ms
{"result": "search_processed_events:agent query=`ark cathie wood daily trades october 12 2026 personalised psnl sale compass pathways cmps buy | ark draftkings dkng meta sale alamar crispr freenome guardant purchase october 2026 `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 2,307 字
Wall Street kicks off key week of bank earnings and CPI data with a mixed session
Cathie Wood’s ARK ETF published their daily trades for Monday, October 12th, 2026, showcasing a series of significant transactions across several sectors. The highlight of the day was ARK’s substantial divestment in Personalised Inc. (NASDAQ:PSNL), selling 730,303 shares through its ARKG ETF, amounting to a total value of $11,684,848. This sale marks a continuation of ARK’s recent trend of reducing its holdings in Personalised Inc.
In contrast, ARK made a notable investment in Compass Pathways PLC (NASDAQ:CMPS), purchasing 284,019 shares via its ARKG ETF, with a total value of $3,408,228. This acquisition suggests ARK’s growing interest in the mental health treatment sector.
Another significant sale involved DraftKings Inc. (NASDAQ:DKNG), where ARK offloaded 229,471 shares across its ARKW and ARKF ETFs, totaling $4,493,042. This is part of an ongoing pattern of reducing exposure to DraftKings over recent days.
On the buying side, ARK continued to build its position in Alamar Biosciences Inc. (NASDAQ:ALMR) by acquiring 101,154 shares through its ARKG ETF, valued at $2,556,161. This follows a previous purchase of 31,068 shares last Friday, indicating a strategic accumulation in the biotech sector.
CRISPR Therapeutics AG (NASDAQ:CRSP) also saw a boost, with ARK acquiring 43,887 shares via its ARKG ETF, amounting to $2,343,126. This purchase aligns with ARK’s ongoing interest in gene-editing technologies.
In smaller trades, ARK added to its holdings in Freenome, Inc. (NASDAQ:FRNM) with a purchase of 136,894 shares worth $2,160,187, and Guardant Health, Inc. (NASDAQ:GH) with 12,720 shares totaling $2,130,218.
Meanwhile, ARK sold 4,520 shares of Meta Platforms, Inc. (NASDAQ:META) through its ARKK ETF, valued at $3,248,388, continuing a pattern of divestment in the tech giant over recent weeks.
These trades reflect Cathie Wood’s dynamic investment strategy, balancing between reducing stakes in certain sectors while increasing exposure to emerging technologies and biotech firms. Investors will be keen to see how these moves align with ARK’s broader market outlook and investment themes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Cathie Wood’s ARK ETF published their daily trades for Monday, October 12th, 2026, showcasing a series of significant transactions across several sectors. The highlight of the day was ARK’s substantial divestment in Personalised Inc. (NASDAQ:PSNL), selling 730,303 shares through its ARKG ETF, amounting to a total value of $11,684,848. This sale marks a continuation of ARK’s recent trend of reducing its holdings in Personalised Inc.
In contrast, ARK made a notable investment in Compass Pathways PLC (NASDAQ:CMPS), purchasing 284,019 shares via its ARKG ETF, with a total value of $3,408,228. This acquisition suggests ARK’s growing interest in the mental health treatment sector.
Another significant sale involved DraftKings Inc. (NASDAQ:DKNG), where ARK offloaded 229,471 shares across its ARKW and ARKF ETFs, totaling $4,493,042. This is part of an ongoing pattern of reducing exposure to DraftKings over recent days.
On the buying side, ARK continued to build its position in Alamar Biosciences Inc. (NASDAQ:ALMR) by acquiring 101,154 shares through its ARKG ETF, valued at $2,556,161. This follows a previous purchase of 31,068 shares last Friday, indicating a strategic accumulation in the biotech sector.
CRISPR Therapeutics AG (NASDAQ:CRSP) also saw a boost, with ARK acquiring 43,887 shares via its ARKG ETF, amounting to $2,343,126. This purchase aligns with ARK’s ongoing interest in gene-editing technologies.
In smaller trades, ARK added to its holdings in Freenome, Inc. (NASDAQ:FRNM) with a purchase of 136,894 shares worth $2,160,187, and Guardant Health, Inc. (NASDAQ:GH) with 12,720 shares totaling $2,130,218.
Meanwhile, ARK sold 4,520 shares of Meta Platforms, Inc. (NASDAQ:META) through its ARKK ETF, valued at $3,248,388, continuing a pattern of divestment in the tech giant over recent weeks.
These trades reflect Cathie Wood’s dynamic investment strategy, balancing between reducing stakes in certain sectors while increasing exposure to emerging technologies and biotech firms. Investors will be keen to see how these moves align with ARK’s broader market outlook and investment themes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
00d01d051c· 2026-10-13 08:08 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前